{
    "eid": "2-s2.0-85107121937",
    "title": "The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?",
    "cover-date": "2021-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Biochemistry",
            "@code": "1303",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Molecular Biology",
            "@code": "1312",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "COVID-19",
        "Cytokine storm",
        "Immune",
        "Inflammation",
        "Interleukin-1",
        "Interleukin-6"
    ],
    "authors": [
        "Gerwyn Morris",
        "Chiara C. Bortolasci",
        "Basant K. Puri",
        "Wolfgang Marx",
        "Adrienne O'Neil",
        "Eugene Athan",
        "Ken Walder",
        "Michael Berk",
        "Lisa Olive",
        "Andre F. Carvalho",
        "Michael Maes"
    ],
    "citedby-count": 46,
    "ref-count": 408,
    "ref-list": [
        "Rewiring the immune response in COVID-19",
        "Clinical and immunological features of severe and moderate coronavirus disease 2019",
        "Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?",
        "COVID-19: consider cytokine storm syndromes and immunosuppression",
        "Cytokine release syndrome in severe COVID-19",
        "Dysregulation of immune response in patients with COVID-19 in Wuhan, China",
        "The pathogenesis and treatment of the \u2018Cytokine Storm' in COVID-19",
        "The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality",
        "Cytokine release syndrome: current perspectives",
        "Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome",
        "Into the eye of the cytokine storm",
        "Toxicity and management in CAR T-cell therapy",
        "Role of platelets in immune system and inflammation",
        "The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing",
        "COVID-19 infection: the perspectives on immune responses",
        "Aveolar macrophage activation and cytokine storm in the pathogenesis of severe COVID-19",
        "COVID-19: melatonin as a potential adjuvant treatment",
        "Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients",
        "IFN-\u03b3 is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection",
        "Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison",
        "Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients",
        "Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)",
        "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
        "Pathological findings of COVID-19 associated with acute respiratory distress syndrome",
        "Fighting COVID-19 exhausts T cells",
        "Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients",
        "Functional exhaustion of antiviral lymphocytes in COVID-19 patients",
        "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients",
        "Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19",
        "COVID-19 pneumonia: different respiratory treatments for different phenotypes?",
        "Covid-19 does not lead to a \u201ctypical\u201d acute respiratory distress syndrome",
        "Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia",
        "The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome",
        "Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1",
        "On the alert for cytokine storm: immunopathology in COVID-19",
        "Hyperferritinemia and inflammation",
        "The pathophysiology of SARS-CoV-2: a suggested model and therapeutic approach",
        "Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: role of lncRNAs in cytokine storm modulation",
        "The SARS-CoV-2 spike protein primes inflammasome-mediated interleukin-1- beta secretion in COVID-19 patient-derived macrophages",
        "Inflammasome formation in the lungs of patients with fatal COVID-19",
        "Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages",
        "Macrophages: a Trojan horse in COVID-19?",
        "Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy",
        "Blocking IL-1 to prevent respiratory failure in COVID-19",
        "Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease",
        "IL-18-dependent MAIT cell activation in COVID-19",
        "Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19",
        "Cytokine storm in COVID-19: the current evidence and treatment strategies",
        "Pulmonary and cardiac pathology in covid-19: the first autopsy series from New Orleans",
        "Pathogenesis of COVID-19 from a cell biologic perspective",
        "Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer",
        "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China",
        "Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection",
        "Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient",
        "A pathological report of three COVID-19 cases by minimally invasive autopsies",
        "Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing",
        "COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome",
        "Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology",
        "The role of neutrophil death in chronic inflammation and cancer",
        "Mineral particles stimulate innate immunity through neutrophil extracellular traps containing HMGB1",
        "The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients",
        "How COVID-19 induces cytokine storm with high mortality",
        "NF-\u03baB signalling as a pharmacological target in COVID-19: potential roles for IKK\u03b2 inhibitors",
        "Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19",
        "Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia",
        "Endothelial cell infection and endotheliitis in COVID-19",
        "Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease",
        "Sepsis: inflammation is a necessary evil",
        "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells",
        "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy",
        "Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights",
        "Endothelial cells as regulators of cytokine storms during influenza infection",
        "The cytokine storm of severe influenza and development of immunomodulatory therapy",
        "Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection",
        "Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection",
        "Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity",
        "Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)",
        "Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China",
        "The laboratory tests and host immunity of COVID-19 patients with different severity of illness",
        "Targeting the \u201ccytokine storm\u201d for therapeutic benefit",
        "COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet",
        "Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza",
        "Cytokines induced during influenza virus infection",
        "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia",
        "Characterizing and controlling the inflammatory network during influenza A virus infection",
        "A question of self-preservation: immunopathology in influenza virus infection",
        "Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex",
        "Clinical aspects and cytokine response in severe H1N1 influenza A virus infection",
        "Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load",
        "Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection",
        "Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study",
        "Clinical factors predictive of pneumonia caused by pandemic 2009 H1N1 influenza virus",
        "Clinical characteristics of 75 pandemic H1N1 influenza patients from Turkey; risk factors for fatality",
        "Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)",
        "Acute cardiac injury events \u226430 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010\u20132012",
        "Acute myocardial infarction and influenza: a meta-analysis of case-control studies",
        "Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review",
        "Influenza, influenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studies",
        "Inflammation and coagulation in the cardiovascular system",
        "Multiple roles of the coagulation protease cascade during virus infection",
        "Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection",
        "Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis",
        "Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia",
        "H1N1 influenza (swine flu)-associated thrombotic microangiopathy with a markedly high plasma ratio of von willebrand factor to ADAMTS13",
        "Influenza virus H1N1 activates platelets through Fc\u03b3RIIA signaling and thrombin generation",
        "Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury",
        "A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells",
        "DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway",
        "Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19",
        "Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection",
        "Influenza virus and endothelial cells: a species specific relationship",
        "The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection",
        "Inflammasome recognition of influenza virus is essential for adaptive immune responses",
        "HMGB1 release by inflammasomes",
        "Damage-associated molecular patterns in inflammatory diseases",
        "Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection",
        "Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm",
        "Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy",
        "Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus",
        "Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells",
        "Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?",
        "Innate immune responses to influenza A H5N1: friend or foe?",
        "Macrophage cytokines: involvement in immunity and infectious diseases",
        "Cytokines in inflammatory disease",
        "Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during <em>Escherichia coli</em> pneumonia in mice",
        "Tumor necrosis factor-\u03b1 signaling in macrophages",
        "Network dynamics determine the autocrine and paracrine signaling functions of TNF",
        "Role of cytokines as a double-edged sword in sepsis",
        "Cytokine regulation of endothelial cell function",
        "The role of inflammatory cytokines in endothelial dysfunction",
        "Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology",
        "Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice",
        "Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge",
        "Infection with MERS-CoV causes lethal pneumonia in the common marmoset",
        "Suppressor of cytokine signaling 3 plays an important role in porcine circovirus type 2 subclinical infection by downregulating proinflammatory responses",
        "Induction of interleukin-1 beta (IL-1\u03b2) is a critical component of lung inflammation during influenza A (H1N1) virus infection",
        "Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection",
        "New fronts emerge in the influenza cytokine storm",
        "Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition",
        "Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung",
        "Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology",
        "The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells",
        "Influenza virus-induced robust expression of SOCS3 contributes to excessive production of IL-6",
        "IL-6 in inflammation, immunity, and disease",
        "The role of interleukin 6 during viral infections",
        "Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling",
        "Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies",
        "Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial",
        "Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers",
        "endothelial cell function, and vascular diseases",
        "Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial",
        "An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells",
        "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells",
        "Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy",
        "CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade",
        "Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy",
        "Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia",
        "Cytokine release syndrome with chimeric antigen receptor T cell therapy",
        "Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia",
        "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia",
        "Controlling cytokine release syndrome to harness the full potential of CAR-based cellular therapy",
        "Toxicities of chimeric antigen receptor T cells: recognition and management",
        "In vivo cell activation following OKT3 administration. systemic cytokine release and modulation by corticosteroids",
        "Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy",
        "Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL",
        "Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412",
        "Cytokine release syndrome",
        "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia",
        "Immunotherapeutic implications of IL-6 blockade for cytokine storm",
        "Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19/CD3-bispecific BiTE antibody blinatumomab",
        "Current concepts in the diagnosis and management of cytokine release syndrome",
        "IL-6 as a keystone cytokine in health and disease",
        "Alternative activation of macrophages: an immunologic functional perspective",
        "Endothelial PPAR-\u03b3 provides vascular protection from IL-1\u03b2-induced oxidative stress",
        "The IL-6-soluble IL-6R\u03b1 autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin",
        "Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis",
        "The pathological and physiological roles of IL-6 amplifier activation",
        "Roles of IL-6-gp130 signaling in vascular inflammation",
        "IL-6 amplifier, NF-\u03baB\u2013triggered positive feedback for IL-6 signaling, in grafts is involved in allogeneic rejection responses",
        "Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome",
        "Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis",
        "Etoposide-based treatment of adult HLH is associated with high biochemical response but poor survival outcomes",
        "Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)",
        "Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies",
        "H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome",
        "Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis",
        "Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3",
        "Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis",
        "Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome",
        "Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children",
        "Fire behind the fury: IL-18 and MAS",
        "Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome",
        "Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome",
        "Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome",
        "Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders",
        "Macrophage activation syndrome: advances towards understanding pathogenesis",
        "Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis",
        "Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis",
        "The immunology of macrophage activation syndrome",
        "Macrophage activation marker soluble CD163 associated with fatal and severe ebola virus disease in humans(1)",
        "Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages",
        "Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis",
        "Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients",
        "Macrophage activation syndrome: early diagnosis is key",
        "Macrophage Activation Syndrome",
        "3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima",
        "Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis",
        "Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis",
        "An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome",
        "Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation",
        "The genetics of macrophage activation syndrome",
        "Rare cause of Hemophagocytic Lymphohistiocytosis due to mutation in PRF1 and SH2D1A genes in two children \u2013 a case report with a review",
        "Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11",
        "Hypercytokinemia in familial hemophagocytic lymphohistiocytosis",
        "Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time",
        "A Heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis",
        "Macrophage activation syndrome induced by A/H1N1 influenza in cystic fibrosis",
        "How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis",
        "Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza",
        "Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome",
        "Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade",
        "Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome",
        "Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management",
        "Natural killer cell responses to viral infection",
        "Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?",
        "The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis",
        "Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases",
        "The pattern of response to anti\u2013interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis",
        "The limited role of interferon-\u03b3 in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness",
        "Specific gene expression profiles in systemic juvenile idiopathic arthritis",
        "Macrophage activation marker neopterin: a candidate biomarker for treatment response and relapse in visceral leishmaniasis",
        "The clinical significance of serum neopterin and adenosine deaminase in patients with secondary hemophagocytic lymphohistiocytosis",
        "Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome",
        "Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis",
        "Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment",
        "Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases",
        "Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis",
        "Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections",
        "Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production",
        "Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses",
        "Interleukin-18: Biological properties and role in disease pathogenesis",
        "Macrophage activation syndrome and cytokine-directed therapies",
        "The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives",
        "Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis",
        "Rapid responses to anakinra in patients with refractory adult-onset Still's disease",
        "Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis",
        "Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically Ill children*",
        "Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome",
        "Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically Ill adult patients with hemophagocytic lymphohistiocytosis",
        "IL-1 acts on T cells to enhance the magnitude of in vivo immune responses",
        "IL-1\u03b2 strikingly enhances antigen-driven CD4 and CD8 T-cell responses",
        "IL-1\u03b2- and IL-4-polarized macrophages have opposite effects on adipogenesis of intramuscular fibro-adipogenic progenitors in humans",
        "The role of interleukin-1 in general pathology",
        "Elevated serum levels of free interleukin-18 in adult-onset Still's disease",
        "Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome",
        "IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome",
        "Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis",
        "Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis",
        "High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein",
        "Interleukin-18 regulates both Th1 and Th2 responses",
        "Regulation of innate CD8+T-cell activation mediated by cytokines",
        "The activation of bystander CD8+ T cells and their roles in viral infection",
        "T cell receptor and cytokine signal integration in CD8+ T cells is mediated by the protein Themis",
        "Interleukin-18-related genes are induced during the contraction phase but do not play major roles in regulating the dynamics or function of the T-cell response to Listeria monocytogenes infection",
        "An IFN-gamma-IL-18 signaling loop accelerates memory CD8+ T cell proliferation",
        "Protection of CD8+ T cells from activation-induced cell death by IL-18",
        "A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy",
        "Targeting the inflammasome in rheumatic diseases",
        "The NLRC4 inflammasome",
        "Anti-viral CD8 T cells and the cytokines that they love",
        "Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease",
        "Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease",
        "The inflammasome in host defense",
        "Epstein-barr virus and innate immunity: friends or foes?",
        "Inflammasomes and their activation",
        "The NLRP3 inflammasome: an overview of mechanisms of activation and regulation",
        "Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis",
        "Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients",
        "Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-\u03b3-producing lymphocytes and IL-6- and TNF-\u03b1-producing macrophages",
        "Transforming growth factor beta downregulates interleukin-1 (IL-1)- induced IL-6 production by human monocytes",
        "Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1\u03b2",
        "Biologics in pediatric rheumatology: quo vadis?",
        "Macrophage activation syndrome in the era of biologic therapy",
        "Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis",
        "Etanercept for therapy-resistant macrophage activation syndrome",
        "Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome",
        "An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder",
        "Macrophage activation syndrome in nine patients: three adults and six children",
        "Worsening of macrophage activation syndrome in a patient with adult onset still's disease after initiation of etanercept therapy",
        "Production of TNF-\u03b1 in macrophages activated by T cells, compared with lipopolysaccharide, uses distinct IL-10\u2013dependent regulatory mechanism",
        "Regulation of M-CSF expression by M-CSF: role of protein kinase C and transcription factor NF kappa B",
        "Macrophage colony stimulating factor regulation by nuclear factor kappa B: a relevant pathway in human immunodeficiency virus type 1 infected macrophages",
        "Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation",
        "A pivotal role of endothelial-specific NF-\u03baB signaling in the pathogenesis of septic shock and septic vascular dysfunction",
        "Linking endothelial dysfunction with endothelial cell activation",
        "Cell type-specific roles of NF-\u03baB linking inflammation and thrombosis",
        "NF-\u03baB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-\u03baB in immune-mediated diseases",
        "The immunopathology of sepsis and potential therapeutic targets",
        "The alternative NF-\u03baB pathway in regulatory T cell homeostasis and suppressive function",
        "Chronic activation of the kinase IKK\u03b2 impairs T cell function and survival",
        "NF-\u03baB: roles and regulation in different CD4(+) T-cell subsets",
        "Activation of apoptosis signalling pathways by reactive oxygen species",
        "The role of reactive oxygen species in regulating T cell-mediated immunity and disease",
        "Mechanisms underlying mouse TNF-alpha stimulated neutrophil derived microparticle generation",
        "Aggregation of \u03b22 integrins activates human neutrophils through the I\u03baB/NF-\u03baB pathway",
        "Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs",
        "Vitamin C: a novel regulator of neutrophil extracellular trap formation",
        "NF-\u03baB signaling in inflammation",
        "Preventing the development of severe COVID-19 by modifying immunothrombosis",
        "IL-6/IL-6 receptor system and its role in physiological and pathological conditions",
        "Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer",
        "Sphingosine-1-phosphate",
        "Sphk1 promotes breast epithelial cell proliferation via NF-\u03baB-p65-mediated cyclin D1 expression",
        "STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer",
        "Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation",
        "Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-\u03baB pathway in human non-small cell lung cancer",
        "A Four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases",
        "Role of IL-6 and IL-17 mediated inflammation amplifier loop in chronic antibody-mediated rejection (CABMR)",
        "Overview of the IL-1 family in innate inflammation and acquired immunity",
        "Interleukin-1 (IL-1) pathway",
        "TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme",
        "IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-\u03baB Activation",
        "Role for anti-cytokine therapies in severe coronavirus disease 2019",
        "NF\u03baB-mediated invasiveness in CD133(+) pancreatic TICs is regulated by autocrine and paracrine activation of IL1 signaling",
        "Interleukin-18 and IL-18 binding protein",
        "NLRP3 inflammasome activation and interleukin-1\u03b2 release in macrophages require calcium but are independent of calcium-activated NADPH oxidases",
        "Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1",
        "Proteome profiling in IL-1\u03b2 and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis",
        "Interleukin-1\u03b2 induced vascular permeability is dependent on induction of endothelial Tissue Factor (TF) activity",
        "Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis",
        "Macrophage activation syndrome and COVID-19",
        "Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis",
        "Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond",
        "Interleukin-6 signaling pathway and its role in kidney disease: an update",
        "Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer",
        "Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis",
        "Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date",
        "Tocilizumab in patients hospitalized with covid-19 pneumonia",
        "Tocilizumab in hospitalized patients with severe covid-19 pneumonia",
        "Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial",
        "Interleukin-6 receptor inhibition in covid-19 \u2014 cooling the inflammatory soup",
        "Tocilizumab for severe COVID-19: a systematic review and meta-analysis",
        "Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6",
        "Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study",
        "IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function",
        "The effects of IL-6 on CD4 T cell responses",
        "Therapeutic uses of anti-interleukin-6 receptor antibody",
        "The role of the JAK/STAT signal pathway in rheumatoid arthritis",
        "The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?",
        "Are Janus kinase inhibitors superior over classic biologic agents in RA patients?",
        "Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study",
        "Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study",
        "Use of baricitinib in patients with moderate and severe COVID-19",
        "Baricitinib plus remdesivir for hospitalized adults with covid-19",
        "The protective effect of rheumatic disease agents in COVID-19",
        "Abstract PO-002: RUXCOVID: A phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19\u2013associated cytokine storm",
        "Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis",
        "Janus kinase inhibitors in autoimmune diseases",
        "Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study",
        "Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations",
        "Viral Inhibition of the IFN-induced JAK/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists",
        "Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway",
        "The complex role of STAT3 in viral infections",
        "STAT3 roles in viral infection: antiviral or proviral?",
        "JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk",
        "The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer",
        "Canakinumab",
        "Canakinumab and cardiovascular outcomes: results of the CANTOS trial",
        "Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis",
        "Canakinumab for Treatment of adult-onset still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial",
        "Canakinumab in a subgroup of patients with COVID-19",
        "Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)",
        "Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study",
        "Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial",
        "Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis",
        "Inhibition of IL1\u03b2 by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial",
        "IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and \u03b2-(1\u20133), (1\u20136)-D-glucan",
        "The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature",
        "Anakinra for severe forms of COVID-19: a cohort study",
        "Anakinra",
        "Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)",
        "Anakinra for rheumatoid arthritis: a systematic review",
        "Anakinra for the treatment of rheumatoid arthritis: a safety evaluation",
        "Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome",
        "Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019",
        "Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series",
        "Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study",
        "Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study",
        "Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis",
        "Inhibition of the NOD-like receptor protein 3 inflammasome is protective in juvenile influenza a virus infection",
        "IL-1RA is part of the inflammasome-regulated immune response in bladder epithelial cells and influences colonization of uropathogenic E. coli",
        "IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice",
        "Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis",
        "Anakinra therapy for non-cancer inflammatory diseases",
        "The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats",
        "Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation",
        "COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms",
        "Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report",
        "Thrombosis in hospitalized patients with COVID-19 in a New York City health system",
        "Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019",
        "Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study",
        "Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19",
        "Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically Ill patients with COVID-19",
        "Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)",
        "Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Geelong",
            "@id": "60018805",
            "affilname": "Deakin University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018805",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60118837",
            "affilname": "Centre for Youth Mental Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60118837",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60118547",
            "affilname": "Melbourne School of Population and Global Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60118547",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Plovdiv",
            "@id": "60031890",
            "affilname": "Medical University of Plovdiv",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031890",
            "affiliation-country": "Bulgaria"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Geelong",
            "@id": "60021050",
            "affilname": "Barwon Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021050",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60016849",
            "affilname": "University of Toronto",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016849",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Cambridge",
            "@id": "123102534",
            "affilname": "C.A.R.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123102534",
            "affiliation-country": "United Kingdom"
        }
    ],
    "funding": [
        "NHMRC"
    ]
}